EuroMAbNet: European Monoclonal Antibodies NetworkEuroMAbNet. European Monoclonal Antibodies Network homepage


Events 11th EuroMabNet Meeting (online version)


17th and 18th of September 2021. One full day on Friday plus half day on Saturday.



Registration form

Registration fees (Euros)
Participants Fees
EuroMAbNet members 0 €
Academia 50 €
Industry 100 €

For further inquiries please contact EuroMAbNet secretary Celia Ramos:

Payment instructions

We accept credit card, PayPal or bank transfer payments.

Bank account details:

Bank: Openbank
Bank Account: 0073 0100 53 0502233517
Account number (IBAN code): ES0600730100530502233517
Bank code (SWIFT/BIC code): OPENESMM
Account owner: EUROMABNET


Registration cancellation and refund policy

No refunds will be made in case of cancellation. Substitutions are acceptable at any time but should be informed by email at

Preliminary Programme

Download programme in PDF format (190 KB)


  • CHAIR: Giovanna Roncador

  • Opening and welcome remarks

  • Invited speaker

  • Sophia Karagiannis Translational Cancer Immunology and Immunotherapy, St. John’s Institute of Dermatology School of Basic & Medical Biosciences, King's College, UK

    IgE class antibodies for cancer immunotherapy

  • Armand Bensussan Immunology, Dermatologie & Oncology, INSERUM, France

    Targeting KIR3DL2/CD158k on Sézay CD4+ T lymphocytes: From bench to bedside

  • Selected student short talk. Speaker to be announced Affiliation

    Title to be disclosed upon grading of submitted abstracts

  • Coffee break

  • CHAIR: Sophia Karagiannis

  • Jose Ignacio Rodriguez Barbosa Laboratory of Transplantation Immunobiology, University of Leon, Spain

    Therapeutic blockade of LIGHT (TNFSF14) interaction with HVEM and LTßR attenuates invivo cytotoxic allogeneic responses

  • Prof. Friedrich Koch-Nolte University Medical Center Hamburg-Eppendorf, Hamburg, Germany

    Nanobody transgenic mice

  • Selected student short talk. Speaker to be announced Affiliation

    Title to be disclosed upon grading of submitted abstracts


  • CHAIR: Vanda Juranić

  • Aurelija Zvirbliene Department of Immunology and Cell Biology Institute of Biotechnology, Vilnius, Lithuania

    The activities of Vilnius University group, a new member of the EuroMabNet

  • Robero Perris Director & Professor of Anatomy and Cell Biology, Parma University

    A Reversed immunoglycomics platform for generating therapeutic antibodies against gly- canation variants of cancer-specific antigens

  • Juan Anguita Inflammation and Macrophage Plasticity Lab & Animal Facility, Biogune, Bilbao, Spain

    Development of Point-Of-Care Diagnostic tools

  • Sponsor talk. Gregor Jainta PEPperPRINT GmbH, HeidelBerg, Germany

    Epitope Mapping and Characterization on Custom Peptide Microarrays

  • Sponsor talk. Bio-Techne

  • Coffee break

  • CHAIR: Berislav Lisnic

  • Ilse Hofmann GPCF Unit Antibodies, German Cancer Research Center, Heidelberg, Germany

    Success stories from the DKFZ core facility unit antibodies: IHC-compatible antibodies used in diagnostics

  • Alnabulsi Ayham Cofounder & CEO of Vertebrate Antibodies Ltd

    B-cell epitope mapping and antigenicity profiling software

  • Jakub Z. Kaczmarek SANOVO BIOTECH A/S

    Title to be announced

  • 'El Alaoui Saïd Covalab

    CovIsoLink, a new enzymatic conjugation for the development of innovative AntibodyDrug Conjugates (ADC) (not confirmed)


  • CHAIR: Pierre Martineau

  • Gabriel Ayme Antibody engineering Platform, Institut Pasteur, France

    Coronabodies : nanobodies directed against the different variants of SARS-CoV-2 proteins

  • Tristan Mangeat Functional screening and targeting in cancer, IRCM INSERM, France

    Selection of environment-modulable antibodies to optimize specificity-toxicity balance of therapeutic antibodies

  • Steve Schoonooghe (VIB) VIB Nanobody Core, VUB - Cellular and Molecular Immunology

    Nanobody-based serum half-life extension of therapeutics

  • Sponsor talk. ChromoTek

  • Coffee break

  • CHAIR: Pierre Lafaye

  • Giovanna Roncador and Pablo Engel CNIO and University of Barcelona

    Title to be confirmed

  • Ludmila Mechetina Laboratory of Immunogenetics, Institute of Molecular and Cellular Biology, Russia

    Nanobodies as potential agents for the generation of HIV-1 broadly neutralizing antibody response

  • José A. Garcia Sanz and Leonor Kremer CIB-CSIC and CNB-CSIC Protein Tools Unit, Madrid, Spain

    Therapeutic potential of 92R mAb on human CCR9+ leukemias in orthotopic xenografts